Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAA 013

Next Previous
X
Search
Drug Profile

TAA 013

Alternative Names: Anti-HER2 ADC - TOT Biopharm; TAA013; Trastuzumab antibody drug conjugate - TOT Biopharm

Latest Information Update: 19 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TOT Biopharm
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HER2 positive breast cancer

Most Recent Events

  • 16 Oct 2023 Discontinued - Phase-III for HER2-positive-breast-cancer in China (IV)
  • 01 Feb 2023 Phase-III development in HER2-positive-breast-cancer is ongoing in China (IV) (TOT Biopharma pipeline, February 2023)
  • 08 Dec 2020 Efficacy and adverse events data from a phase I trial in HER2-positive-breast-cancer presented at the 43rd Annual San Antonio Breast Cancer Symposium (SABCS-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top